R K Ramanathan1, M L Rothenberg2, A de Gramont3, C Tournigand3, R M Goldberg4, S Gupta5, T André6. 1. TGen Clinical Research Services at Scottsdale Healthcare, Scottsdale, AZ. Electronic address: rramanathan@tgen.org. 2. Vanderbilt-Ingram Cancer Center, Nashville, TN. 3. Hôpital Saint-Antoine, APHP, UPMC univ Paris 06, INSERM U8106, GERCOR, Paris, France. 4. Division of Hematology-Oncology, Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC. 5. International Clinical Development Oncology, Sanofi-aventis, Malvern, PA, USA. 6. Service d'Hépato-Gastro-Entérologie, Group Hospitalier Pitié-Salpêtrière, Paris, France.
Abstract
BACKGROUND: The purpose of this study was to determine whether the presence of diabetes mellitus (DM) influences the incidence, severity, and/or course of peripheral sensory neuropathy (PSN) after oxaliplatin (FOLFOX) therapy in patients with colorectal cancer (CRC). METHODS: A retrospective pooled analysis incorporating three phase III studies was conducted: Multicenter International Study of Oxaliplatin, 5-Fluorouracil, and Leucovorin in the Adjuvant Treatment of Colon Cancer (MOSAIC) (adjuvant treatment; stage II/III colon cancer), EFC4584 (second-line treatment; metastatic CRC), and EFC2962 (first-line treatment; metastatic CRC). Patients were ineligible for the studies if they had known PSN (EFC4584) or PSN grade > or =1 (MOSAIC and EFC2962) at baseline. The incidence of PSN was evaluated retrospectively in patient subgroups with or without DM at baseline that received FOLFOX. Kaplan-Meier curves were used to assess the probability of PSN with increasing cumulative oxaliplatin dose. RESULTS: Of 1587 patients enrolled across the three studies, 135 (8.5%) had DM at baseline. The incidence of PSN (non-DM/DM) was 45.0%/46.7% (grade 1), 28.6%/26.7% (grade 2), and 13.0%/12.6% (grade 3). The probability of PSN by cumulative dose of oxaliplatin was similar in DM and non-DM patients. CONCLUSIONS: This retrospective analysis indicates that oxaliplatin-based therapy does not influence the incidence, severity, or time to onset of PSN in asymptomatic DM patients with CRC who meet eligibility criteria for clinical trials.
BACKGROUND: The purpose of this study was to determine whether the presence of diabetes mellitus (DM) influences the incidence, severity, and/or course of peripheral sensory neuropathy (PSN) after oxaliplatin (FOLFOX) therapy in patients with colorectal cancer (CRC). METHODS: A retrospective pooled analysis incorporating three phase III studies was conducted: Multicenter International Study of Oxaliplatin, 5-Fluorouracil, and Leucovorin in the Adjuvant Treatment of Colon Cancer (MOSAIC) (adjuvant treatment; stage II/III colon cancer), EFC4584 (second-line treatment; metastatic CRC), and EFC2962 (first-line treatment; metastatic CRC). Patients were ineligible for the studies if they had known PSN (EFC4584) or PSN grade > or =1 (MOSAIC and EFC2962) at baseline. The incidence of PSN was evaluated retrospectively in patient subgroups with or without DM at baseline that received FOLFOX. Kaplan-Meier curves were used to assess the probability of PSN with increasing cumulative oxaliplatin dose. RESULTS: Of 1587 patients enrolled across the three studies, 135 (8.5%) had DM at baseline. The incidence of PSN (non-DM/DM) was 45.0%/46.7% (grade 1), 28.6%/26.7% (grade 2), and 13.0%/12.6% (grade 3). The probability of PSN by cumulative dose of oxaliplatin was similar in DM and non-DMpatients. CONCLUSIONS: This retrospective analysis indicates that oxaliplatin-based therapy does not influence the incidence, severity, or time to onset of PSN in asymptomatic DMpatients with CRC who meet eligibility criteria for clinical trials.
Authors: Pauline A J Vissers; Floortje Mols; Melissa S Y Thong; Frans Pouwer; Gerard Vreugdenhil; Lonneke V van de Poll-Franse Journal: J Cancer Surviv Date: 2015-02-03 Impact factor: 4.442
Authors: Haifaa Dbouk; Simon Mentha; Deborah Mukherji; Jean Lee; Ali Haydar; Ali Shamseddine; Eileen M O'Reilly; Leonard Saltz; Ghassan K Abou-Alfa Journal: Gastrointest Cancer Res Date: 2014-03
Authors: Arya Shah; E Matthew Hoffman; Michelle L Mauermann; Charles L Loprinzi; Anthony J Windebank; Christopher J Klein; Nathan P Staff Journal: J Neurol Neurosurg Psychiatry Date: 2018-02-08 Impact factor: 10.154
Authors: Hannah C Timmins; David Mizrahi; Tiffany Li; Matthew C Kiernan; David Goldstein; Susanna B Park Journal: J Cancer Surviv Date: 2021-01-12 Impact factor: 4.442
Authors: Susana Pereira; Filipa Fontes; Teresa Sonin; Teresa Dias; Maria Fragoso; José M Castro-Lopes; Nuno Lunet Journal: Support Care Cancer Date: 2015-09-18 Impact factor: 3.603
Authors: Sunita Padman; Jaein Lee; Rajiv Kumar; Mark Slee; Paul Hakendorf; Alison Richards; Bogda Koczwara; Ganessan Kichenadasse; Shawgi Sukumaran; Amitesh Roy; Sina Vatandoust; Christos S Karapetis Journal: Support Care Cancer Date: 2014-09-16 Impact factor: 3.603